Efficacy and safety of sintilimab in combination with lenvatinib therapy as second-line regimen for patients with unresectable hepatocellular carcinoma

WANG Junjie; XU Long; YUAN Guosheng; XU Xiaoming; ZHOU Xiaoyuan; LUO Runqi

doi:10.3969/j.issn.1006-5725.2022.09.016

Home>Articles>Efficacy and safety of sintilimab in combination with lenvatinib therapy as second-line regimen for patients with unresectable hepatocellular carcinoma

DOI: 10.3969/j.issn.1006-5725.2022.09.016

Efficacy and safety of sintilimab in combination with lenvatinib therapy as second-line regimen for patients with unresectable hepatocellular carcinoma

WANG Junjie

XU Long

YUAN Guosheng

XU Xiaoming

ZHOU Xiaoyuan

LUO Runqi

Machine-generated Keywords：

Publication Date：2022-05-10

Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)

Pages：6( 1130-1135 )

The Journal of Practical Medicine

ISTICPKU

ISSN：1006-5725

Year, Vol.(Issue)：2022,38(9)